- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01718691
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Fukuoka, Japan
- Research Site
-
Kagoshima, Japan
- Research Site
-
Kyoto, Japan
- Research Site
-
Nagasaki, Japan
- Research Site
-
Tokyo, Japan
- Research Site
-
-
Aichi
-
Nagoya, Aichi, Japan
- Research Site
-
-
Chiba
-
Kashiwa, Chiba, Japan
- Research Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
- Research Site
-
-
Kanagawa
-
Isehara, Kanagawa, Japan
- Research Site
-
-
Miyagi
-
Sendai, Miyagi, Japan
- Research Site
-
-
Osaka
-
Moriguchi, Osaka, Japan
- Research Site
-
-
Shimane
-
Izumo, Shimane, Japan
- Research Site
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japan
- Research Site
-
-
Tochigi
-
Utsunomiya, Tochigi, Japan
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients who are histopathologically confirmed to have the following cluster of differentiation 20 (CD20) positive low-grade B cell non-Hodgkin's lymphoma or mantle cell lymphoma by lymph node biopsy or evaluable tissue biopsy within 6 months before the registration WHO Classification of Tumors (fourth edition):
- Small lymphocytic lymphoma
- Splenic marginal zone B-cell lymphoma
- Lymphoplasmacytic lymphoma
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
- Nodal marginal zone B-cell lymphoma
- Follicular lymphoma (Grade 1, 2, 3a)
- Mantle cell lymphoma
- Patients with a measurable lesion ( > 1.5 cm in major axis on CT)
- Patients without a medical history
Patients with at least 1 of the following clinical symptoms or signs (excluding mantle cell lymphoma):
- Bulky disease measuring > 7 cm in major axis on CT (excluding spleen)
B symptoms
- Fever exceeding 38.0ºC of unknown cause
- Night sweats
- Weight decrease exceeding 10% within 6 months before patient registration
- Elevated serum LDH or beta 2 microglobulin
- Three or more regional lymph nodes of > 3 cm in major axis on CT
- Symptomatic splenomegaly
- Intracranial pressure
- Pleural effusion/ascites retention
- Patients expected to live for at least 3 months
- Patients aged between 20 and 79 years (at the time of registration)
- Patients whose Eastern Cooperative Oncology Group (ECOG) performance status (P.S.) is 0~2
Patients with adequately maintained major organ function (bone marrow, heart, lungs, liver, kidneys)
- Neutrophil count: not less than 1,500 /mm3
- Platelet count: not less than 75,000 /mm3
- Aspartate aminotransferase (AST)[Glutamic oxaloacetic transaminase (GOT)]: not more than 3 times the standard upper limit for the site
- Alanine aminotransferase (ALT)[Glutamic pyruvic transaminase (GPT)]: not more than 3 times the standard upper limit for the site
- Total bilirubin: not more than 1.5 times the standard upper limit for the site
- Serum creatinine: not more than 1.5 times the standard upper limit for the site
- Arterial partial pressure of oxygen (PaO2): not less than 65 mmHg
- Electrocardiogram shows no abnormal findings that require treatment
- Echocardiogram of left ventricular ejection fraction (LVEF): not less than 55%
- Patients whose informed consent has been obtained in person
Exclusion Criteria:
Patients who fall under any one of the following criteria are to be excluded
- Patients whose transformation has been confirmed histopathologically
- Mantle cell lymphoma patients aged 65 years or younger
- Patients who were administered or received transfusion of cytokine formulations such as G-CSF (granulocyte colony stimulating factor) and erythropoietin within 14 days before pre-registration test
- Patients with severe active infectious disorders (receiving antibiotics, antifungals, or antivirus IV injection)
- Patients with serious complications (such as hepatic or renal failure)
- Patients with severe complications of cardiac disease (examples: myocardial infarction, ischemic heart disease) or its previous history within 2 years before patient registration, and patients with arrhythmia requiring a treatment
- Patients with serious gastrointestinal conditions (persistent or severe nausea/vomiting or diarrhea)
- Patients who are positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody or HIV antibody [if HBs or hepatitis B core (HBc) positive, patients whose hepatitis B virus (HBV)-DNA test results indicate positive]
- Patients with serious bleeding tendencies [such as disseminated intravascular coagulation (DIC)]
- Patients having or suspected of having symptoms indicative of the central nervous system (CNS) involvement
- Patients with interstitial pneumonitis, pulmonary fibrosis, pulmonary emphysema complications requiring treatment or its medical history.
- Patients with active multiple primary cancer
- Patients who received chemotherapy, radiotherapy, antibody therapy and antitumor steroid therapy in the past
- Patients with complications or medical history of autoimmune haemolytic anaemia
- Patients who were administered investigative or unapproved drugs within 3 months before patient registration
- Patients with addiction to drugs or narcotics, or alcoholism
- Patients who have previously received hematopoietic stem cell transplantation
- Patients who are or may be pregnant, lactating patients
- Patients, whether male or female, who do not agree to use contraception
- Patients otherwise judged by the investigator or the sub-investigator to be unsuitable for inclusion in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SyB L-0501+rituximab
|
A dose of 90 mg/m^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation.
This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
A dose of 375 mg/m^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation.
This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1.
However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
Time Frame: Up to 30 weeks
|
The criteria for CR and CRu based on IWRC are shown below. CR: Fulfills all of the following
CRu: Fulfills all of the following
|
Up to 30 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
Time Frame: Up to 30 weeks
|
The criteria for PR based on IWRC are shown below. PR: SPD regressed > 50% |
Up to 30 weeks
|
Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
Time Frame: Up to 30 weeks
|
The criteria for CR based on the Revised RC are shown below. Definition: Disappearance of all evidence of disease Nodal Masses:
Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. |
Up to 30 weeks
|
Overall Response Rate (PR or Better) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
Time Frame: Up to 30 weeks
|
The criteria for PR based on the Revised RC are shown below. Definition: Regression of measurable disease and no new sites Nodal Masses: 50% or more decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes
Spleen, Liver: 50% or more decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified. |
Up to 30 weeks
|
Complete Response Rate Based on WHO Handbook for Reporting Results of Cancer Treatment (1979)
Time Frame: Up to 30 weeks
|
The criteria for Complete response based on WHO Handbook for Reporting Results of Cancer Treatment (1979) are shown below. Measurable disease: The disappearance of all known disease, determined by 2 observations not less than 4 weeks apart. Unmeasurable disease: Complete disappearance of all known disease for at least 4 weeks. Bone metastases: Complete disappearance of all lesions on X-ray or scan for at least 4 weeks. |
Up to 30 weeks
|
Overall Response Rate (PR or Better) Based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)"
Time Frame: Up to 30 weeks
|
The criteria for Overall response rate (PR or better) based on "WHO Handbook for Reporting Results of Cancer Treatment (1979)" are shown below. Definition of PR: Measurable disease: 50% or more decrease in total tumor size of the lesions which have been measured to determine the effect of therapy by 2 observations not less than 4 weeks apart. In addition there can be no appearance of new lesions or progression of any lesion. Unmeasurable disease: Estimated decrease in tumor size of 50% or more for at least 4 weeks. Bone metastases: Partial decrease in size of lytic lesions, recalcification of lytic lesions, or decreased density of blastic lesions for at least 4 weeks. |
Up to 30 weeks
|
Progression-Free Survival (PFS)
Time Frame: Up to 30 weeks
|
PFS is the period from registration date to the earliest onset date of any progression event calculated using the Kaplan-Meier estimator. The median and the 95% confidence interval (CI) were calculated using Greenwood's formula. Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause. The date of progression was determined based on overall response assessed using IWRC, Revised RC, and WHO, and assessment by the primary physicians (excluding overall response). |
Up to 30 weeks
|
Duration of Response (DOR)
Time Frame: Up to 30 weeks
|
DOR is the period from the date of achieving CR, CRu or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. The date of achieving CR, CRu or PR was determined based on the overall response assessed using IWRC. The date of progression was determined based on overall response assessed using IWRC, Revised RC and WHO, and assessment by the primary physicians (excluding overall response). Progression event was defined as progression (includes recurrence/relapse), initiation of post-study treatment, confirmation of other malignant tumor, or death due to any given cause. |
Up to 30 weeks
|
Overall Survival (OS)
Time Frame: Up to 30 weeks
|
Death due to any given cause was defined as an event.
OS was calculated using the Kaplan-Meier estimator.
The median and the 95% CI were calculated using Greenwood's formula.
|
Up to 30 weeks
|
Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Discontinuation Due to Adverse Event
Time Frame: up to 30 weeks
|
Adverse events were evaluated using Common Terminology Criteria for Adverse Events (CTCAE) v4.0,
Japan Clinical Oncology Group/Japan Society of Clinical Oncology (JCOG/JSCO) version, and were encoded using Medical Dictionary for Regulatory Activities (MedDRA) Ver.16.1.
|
up to 30 weeks
|
Laboratory Test Abnormalities (Biochemical Tests)
Time Frame: up to 30 weeks
|
Abnormalities in laboratory test values in overall study period were analyzed.
Severity of abnormalities were evaluated using CTCAE.
Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE
|
up to 30 weeks
|
Laboratory Test Abnormalities (Hematology Tests)
Time Frame: up to 30 weeks
|
Abnormalities in laboratory test values in overall study period were analyzed.
Severity of abnormalities were evaluated using CTCAE.
Grade 1 : mild Grade 2 : moderate Grade 3 : severe or medically significant but not immediately life-threatening Grade 4 : life threatening or disabling Grade 5 : death related to AE
|
up to 30 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- 2011002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low-grade B Cell Non-Hodgkin's Lymphoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
BiogenCompletedLow-Grade or Follicular B-Cell Non-Hodgkin's LymphomaUnited States, Canada
-
BayerCompletedLymphoma, B-Cell | Non-Hodgkin's Lymphoma | Lymphoma, Low-GradeJapan
-
Eisai Inc.CompletedNon-Hodgkin's Lymphoma | Lymphoma, B-cell | Lymphoma, Low-gradeUnited States
-
AmgenCompletedLymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
-
Eden BioCell Ltd.National Taiwan University HospitalTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryTaiwan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Novartis PharmaceuticalsCompletedMantle Cell Lymphoma | Gray Zone Lymphoma | Hodgkin's Disease | CD20+, B-cell Lymphomas | Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL) | Transformed Lymphoma/DLBCL/PMBCLUnited States
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingNon Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | NHL | High-grade B-cell LymphomaUnited States
Clinical Trials on SyB L-0501
-
SymBio PharmaceuticalsCompletedChronic Lymphocytic LeukemiaJapan
-
SymBio PharmaceuticalsCompletedRelapsed/Refractory Multiple MyelomaJapan
-
SymBio PharmaceuticalsCompleted
-
SymBio PharmaceuticalsCompleted
-
SymBio PharmaceuticalsTerminated
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell LymphomaJapan
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkCompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain NeoplasmUnited States
-
SymBio PharmaceuticalsCompleted
-
Boehringer IngelheimCompleted